REENA JOHN: Open Payments
NPI 1801042528 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$825 in 35 payments from 9 companies in 2025. Trend: 2023 $536 · 2024 $824 · 2025 $825
Food & beverage: $825
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $387 |
| Bayer Healthcare Pharmaceuticals Inc. | 19 | $183 |
| RECORDATI_RARE_DISEASES_INC. | 1 | $110 |
| GlaxoSmithKline, LLC. | 1 | $30 |
| Amgen Inc. | 1 | $27 |
| Novo Nordisk Inc | 1 | $27 |
| Lilly USA, LLC | 1 | $24 |
| Exact Sciences Corporation | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $16 |
Products named: Kerendia, FARXIGA, BREZTRI, ISTURISA, AIRSUPRA, TRELEGY ELLIPTA, OTEZLA, JARDIANCE.
Industry payments across NV — which companies pay providers there.
